Health · Planned · 3 sources combinedp. 1 / 1
Domestic COVID-19 vaccine
Phase 1 clinical trial begins
In short
Ajigen Consortium has begun Phase 1 clinical trials of the domestic COVID-19 mRNA vaccine candidate BMI2012.
The study will evaluate safety and immune response in healthy adults aged 19 to 55.
Trials are scheduled to be completed by December, with a target to enter Phase 2 clinical trials in the second half of 2027.
Key facts
| When | First Phase 1 administration began on October 28 and was announced on October 29. |
|---|---|
| Who | Jointly developed by Ajigen, Korea BMI, MicroUni, and Medicibio Consortium. |
| What | Phase 1 clinical trial of 'BMI2012', a COVID-19 mRNA vaccine candidate made with domestic technology. |
| How | Adults aged 19-55 will receive injections at three hospitals including Korea University Guro Hospital to evaluate safety and dosage. |
What it means for me
COVID-19 mRNA vaccine localization is in progress and is unrelated to general public vaccination.
